Literature DB >> 1510

Elementary osmotic pump.

F Theeuwes.   

Abstract

The elementary osmotic pump is a new delivery system for drugs or other active agents; it delivers the agent by an osmotic process at a controlled rate. Control resides in the: (a) water permeation characteristics of a semipermeable membrane surrounding the formulated agent, and (b) osmotic properties of the formulation. In its simplest embodiment, the system is constructed by coating an osmotically activie solid agent with the rate-controlling, semipermeable membrane. This membrane contains an orifice of critical size through which solubilized agent is dispensed. The system can contain the agent in solid form at loading higher than 90% of the total volume, and the agent can be delivered at rates several orders of magnitude higher than can be achieved by solution diffusion through polymeric membranes. The delivery rate, the fraction of total content delivered at zero order, and the system's delivery portal size have been calculated for delivery of a single compound. Experimental work verified the theory. The release rate from the system was found to be independent of outside agitation when the system is not deformed by shaking action, the pH of the environment, and delivery portal size for sizes within a specified range. The delivery rate from this system in vitro and in the GI tract of dogs was found to be equal.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1510     DOI: 10.1002/jps.2600641218

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  64 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-beta-CD.

Authors:  K Okimoto; A Ohike; R Ibuki; O Aoki; N Ohnishi; T Irie; K Uekama; R A Rajewski; V J Stella
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Two-step solid lipid extrusion as a process to modify dissolution behavior.

Authors:  Maike Windbergs; Sinan Gueres; Clare J Strachan; Peter Kleinebudde
Journal:  AAPS PharmSciTech       Date:  2010-03-23       Impact factor: 3.246

5.  Constant potassium chloride release from microporous membrane-coated tablets prepared with aqueous colloidal polymer dispersions.

Authors:  R Bodmeier; O Paeratakul
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

6.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

7.  Development of push-pull osmotic tablets using chitosan-poly(acrylic acid) interpolymer complex as an osmopolymer.

Authors:  Wichan Ketjinda; Nuttanan Sinchaipanid; Pichet Limsuwan; Hans Leuenberger; Ampol Mitrevej
Journal:  AAPS PharmSciTech       Date:  2010-12-23       Impact factor: 3.246

Review 8.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

9.  Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility.

Authors:  Anil K Philip; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2006-07-07       Impact factor: 3.246

10.  Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7m-beta-CD.

Authors:  K Okimoto; M Miyake; N Ohnishi; R A Rajewski; V J Stella; T Irie; K Uekama
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.